ENVERIC BIOSCIENCES INC (ENVB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.39-3.47%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ENVB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
ENVB — debt issuance
Dated 2026-06-09
Other Events. On June 9, 2026, Enveric Biosciences, Inc. (the “Company”) filed a prospectus supplement (the “Prospectus Supplement”) to offer an additional $2,425,000 of shares (the “Shares”) of its common stock, par value $0.01 per share (“Common Stock”), issuable pursuant to the At The Market Offering Agreement between the Company and H.C. Wainwright & Co., LLC (the “Sales Agent”), dated April 9, 2025 (the “ATM Agreement”). Prior to the date hereof, the Company has sold an aggregate of $4,4…
Why it matters: Raising money through warrant exercises helps ongoing development. This is key for funding IND submission and clinical trials.
Supportive ifThe company reports at least $5 million raised from warrant exercises by Q3 2026.
Worry ifWarrant exercises do not bring in enough money. This hurts funding for operations.
Why it matters: Keeping patent protection is key for the company's edge and future deals. New patents could boost market value.
Supportive ifThe company announces new patents or notices of allowance for its compounds by the end of Q3 2026.
Worry ifNo new patents or allowances are reported. This shows possible weaknesses in the IP strategy.
Why it matters: Updates on these patents can help Enveric in the market. They protect its ideas. Strong IP can bring in partners and funding.
Supportive ifNew patents are granted or notices of allowance are received for EVM401 and EVM301.
Worry ifNo new patents or approvals are reported. This shows possible problems with IP protection.
Why it matters: Higher losses would show the company is still struggling to manage cash burn. Investors look for signs of financial stability.
Worry ifQ2 operating losses were over $2M.
Less concerning ifOperating losses were under $2M.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$262 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $1,157 loss on $10,000 · 11.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,936 loss on $10,000 · 89.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Getting money from equity is key for operations. Large offerings show financial strength.
Supportive ifTotal equity offerings in Q2 exceed $2.5M.
Worry ifNo equity offerings or total offerings below $2.5M in Q2.
Why it matters: Submitting the IND application is an important step. It helps start clinical trials for EB-003. This could prove the drug's value and attract investors.
Supportive ifThe company submits the IND application for EB-003 by the end of Q3 2026.
Worry ifThe company will delay the IND application submission past Q3 2026.